AbCellera Biologics (ABCL) Enterprise Value (2020 - 2025)
Historic Enterprise Value for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$520.7 million.
- AbCellera Biologics' Enterprise Value rose 2207.13% to -$520.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$520.7 million, marking a year-over-year increase of 2207.13%. This contributed to the annual value of -$650.6 million for FY2024, which is 1718.1% up from last year.
- Latest data reveals that AbCellera Biologics reported Enterprise Value of -$520.7 million as of Q3 2025, which was up 2207.13% from -$578.1 million recorded in Q2 2025.
- AbCellera Biologics' 5-year Enterprise Value high stood at -$517.7 million for Q3 2021, and its period low was -$1.0 billion during Q2 2022.
- For the 5-year period, AbCellera Biologics' Enterprise Value averaged around -$734.8 million, with its median value being -$748.0 million (2021).
- As far as peak fluctuations go, AbCellera Biologics' Enterprise Value tumbled by 6770.64% in 2022, and later surged by 2216.38% in 2023.
- Quarter analysis of 5 years shows AbCellera Biologics' Enterprise Value stood at -$748.0 million in 2021, then dropped by 21.86% to -$911.5 million in 2022, then increased by 13.81% to -$785.6 million in 2023, then rose by 17.18% to -$650.6 million in 2024, then increased by 19.97% to -$520.7 million in 2025.
- Its last three reported values are -$520.7 million in Q3 2025, -$578.1 million for Q2 2025, and -$630.3 million during Q1 2025.